Literature DB >> 19546681

Should we hesitate to use subcutaneous tunneling for fear of damaging the sural flap pedicle?

Fatih Uygur1, Rahmi Evinç, Nurettin Noyan, Haluk Duman.   

Abstract

BACKGROUND: The distally based sural nerve flap is a preferable option for covering defects of the lower third of the leg. However, many authors noted that in particular pressure exerted by tunneling of the flap pedicle could be harmful. Thus, they either inset the pedicle or exteriorize the pedicle to decrease complications.
METHODS: We used distally based superficial sural artery island flaps for the reconstruction of defects of the lower leg, the ankle, and malleolus in 12 patients between 2004 and 2008 without tunelization. The defects were covered with no major complications.
RESULTS: In 3 flaps, there was a small amount of distal marginal necrosis, which was excised and closed spontaneously or skin grafted.
CONCLUSION: We concluded that unless there are certain risk factors such as arterial hypertension, diabetes, peripheral vascular disease, and vasculitis, avoiding a subcutaneous tunneling is not necessary.

Entities:  

Mesh:

Year:  2009        PMID: 19546681     DOI: 10.1097/SAP.0b013e318184aba2

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  3 in total

Review 1.  Soft tissue management of war wounds to the foot and ankle.

Authors:  Martin F Baechler; Adam T Groth; Leon J Nesti; Barry D Martin
Journal:  Foot Ankle Clin       Date:  2010-03       Impact factor: 1.653

Review 2.  How Safe Is Reverse Sural Flap?: A Systematic Review.

Authors:  Sanjib Tripathee; Surendra Jung Basnet; Apar Lamichhane; Lynda Hariani
Journal:  Eplasty       Date:  2022-06-03

3.  Clinical experience of biliary T tube of immobilization of peri-pin membrane in tibial Gustilo III fracture treated with vacuum sealant drainage combined with an external fixator.

Authors:  Hui Ye; Shufeng Lin; Junfeng Zhu; Lifeng Jiang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.